Why Saw Palmetto Is in Male Vitality Formulas — and What the Large Trials Actually Found

Primordial Vigor X Editorial Team
Independent supplement research · Updated 4 August 2026

10 min read · 8 cited sources

Quick Answer: What Did the Large Saw Palmetto Trials Actually Find?

The biggest and best-designed trial, CAMUS, escalated saw palmetto from 320 mg to 960 mg a day over 72 weeks in 369 men and found no advantage over placebo on any measured outcome — which is worth knowing before you buy any formula that includes it. The earlier STEP trial, at the standard 320 mg dose for a year, reached the same conclusion. The 2024 Cochrane update pooled 27 randomised trials in 4,656 men and concluded that saw palmetto alone provides little to no benefit for urinary symptoms.

Largest trial: CAMUS, 369 men, 320 → 640 → 960 mg over 72 weeks, no benefit over placebo.
Reassuring finding: saw palmetto did not raise or mask PSA, even at 960 mg a day.
Why it is still in blends: a laboratory DHT-pathway rationale, which is a mechanism rather than a proven outcome.

Natural ingredients badge used on Primordial Vigor X marketing material — Sourcing badges of this kind describe how a formula is made. They are marketing marks, not clinical evidence for any ingredient inside it — which is exactly why the trial record below matters more than the label art.

What saw palmetto is, and the two different questions people ask about it

Saw palmetto is an extract of the berry of Serenoa repens, a fan palm native to the south-eastern United States. It turns up in two kinds of product: prostate and urinary-comfort supplements for men over 50, and general male-vitality blends like the one this site covers. Those uses rest on different questions, and confusing them is the most common mistake in the coverage of this ingredient.

The first — does saw palmetto improve lower urinary tract symptoms in men with an enlarged prostate? — has been tested repeatedly, at scale, with public money. The second — does its laboratory enzyme effect translate into anything a healthy man would notice? — has barely been tested. Almost all the evidence below answers the first question.

The trial record, in one table

Every row is a published, retrievable study. Note the pattern: the larger the trial, the more clearly null the result.

Trial	Design	n	Dose	Duration	Primary outcome	Result
CAMUS (Barry MJ et al., JAMA 2011;306(12):1344–1351; NCT00603304)	Randomised, double-blind, placebo-controlled, multicentre, 11 North American sites	369 men aged 45+, AUA Symptom Index 8–24	Ethanolic extract, escalating: 320 mg → 640 mg → 960 mg per day, stepped at 6-month intervals	72 weeks (18 months' exposure)	Change in AUA Symptom Index	Null. Mean change −2.20 points on saw palmetto vs −2.99 on placebo. No benefit on peak flow, prostate size, post-void residual volume or quality of life.
CAMUS PSA analysis (Andriole GL et al., J Urol 2013;189(2):486–492; DOI 10.1016/j.juro.2012.09.037)	Pre-planned analysis within CAMUS	369 (same cohort)	Same escalation to 960 mg/day	72 weeks	Change in serum PSA	No masking. Mean PSA change 0.16 ng/mL (SD 1.08) on placebo vs 0.23 ng/mL (SD 0.83) on saw palmetto. Saw palmetto did not lower PSA even at high dose.
CAMUS safety analysis (Avins AL et al., J Urol 2013; DOI 10.1016/j.juro.2012.10.002)	Safety and toxicity analysis within CAMUS	357 in the modified intention-to-treat set	Up to 960 mg/day, three times the usual dose	18 months	Adverse events, vital signs, laboratory panels	No evidence of toxicity. No significant differences in serious or non-serious adverse events, vital signs, laboratory abnormalities or withdrawal rates.
STEP (Bent S et al., N Engl J Med 2006;354(6):557–566; DOI 10.1056/NEJMoa053085)	Randomised, double-blind, placebo-controlled	225 men aged over 49 with moderate-to-severe symptoms	160 mg twice daily (320 mg/day)	1 year	AUA Symptom Index and maximal urinary flow rate	Null. No significant difference from placebo on either primary outcome.
Cochrane update 2024 (Franco JV et al., World J Mens Health 2024;42(3):518–530; DOI 10.5534/wjmh.230222)	Systematic review and meta-analysis of randomised trials	27 trials, 4,656 participants	Varied (monotherapy and combinations)	Short and long-term follow-up	Urologic symptom scores, quality of life, adverse events	Little to no benefit. Mean difference −0.90 on the IPSS scale at short-term follow-up; little to no difference in quality of life; probably little to no difference in adverse events.

A note on scale: roughly three points on the AUA Symptom Index is usually taken as the smallest difference a man would notice. Both CAMUS arms moved about that much — the classic signature of a placebo response rather than a drug effect.

The PSA finding is the part worth knowing

Buried inside a null trial is a useful result for men over 50. A recurring worry has been that, by acting on the same enzyme pathway as prescription 5-alpha-reductase inhibitors, saw palmetto might suppress PSA and hide a rising reading. Finasteride and dutasteride do roughly halve PSA, and clinicians correct for it.

The CAMUS PSA analysis tested that directly, at doses up to three times what any supplement label recommends, and found nothing: 0.16 ng/mL mean change on placebo against 0.23 ng/mL on saw palmetto. NCCIH states plainly that saw palmetto does not appear to affect PSA readings. That is a null result you can be pleased about — though not a reason to skip a screening conversation with a clinician.

Where Primordial Vigor X sits in this

Saw palmetto berry is one of three named botanicals in the 870 mg daily capsule, alongside Tongkat Ali and Tribulus terrestris. We publish the trial record for each — null results included.

Order From Official Store

So why is it in male vitality formulas?

Because of a mechanism, not because of those trials. This is the distinction nobody in the consumer coverage draws cleanly.

Testosterone is converted into a more potent androgen, dihydrotestosterone or DHT, by the enzyme 5-alpha-reductase. DHT is the androgen most implicated in prostate growth and male-pattern hair loss. Memorial Sloan Kettering's monograph describes the laboratory findings: saw palmetto inhibits 5-alpha-reductase, reduced tissue uptake of both testosterone and DHT by more than 40%, and inhibited binding of DHT to its receptor.

That is why formulators reach for it. As a rationale it is coherent; as evidence it is thin.

Most of that work is laboratory work — cell and tissue studies, not men swallowing capsules. Effects measured in tissue at controlled concentrations do not automatically appear in someone taking 320 mg orally once a day.
The human trials measured a different endpoint. CAMUS and STEP asked whether men felt and urinated better. Neither was designed to test whether serum DHT moved in a healthy man, so their null results do not disprove the mechanism — they simply do not address it.
Nobody has run the trial that would settle it. There is no large randomised study of saw palmetto in healthy men measuring androgen ratios as a primary outcome.

A null result on urinary symptoms is therefore not the same as a null result on the reason saw palmetto is in a vitality blend. But an untested hypothesis is not a benefit, and should not be sold as one.

Interactions and cautions, from the sources that specialise in them

This is the one part of the saw palmetto question where the authoritative sources are unambiguous and worth quoting rather than paraphrasing.

Blood thinners and antiplatelet drugs. Memorial Sloan Kettering's monograph states saw palmetto may increase the risk of bruising and bleeding with warfarin or other blood thinners, and advises avoiding it alongside anticoagulants, antiplatelet drugs or NSAIDs. The Merck Manual agrees. This rests largely on case reports, and CAMUS found no toxicity signal at high dose in a screened population — but a trial cohort is not your medication list. Ask your doctor, and tell a surgical team well before any procedure.

Hormone therapy and oral contraceptives. The Merck Manual notes a possible interaction with oestrogen therapy and oral contraceptives. Saw palmetto should be avoided by anyone pregnant or who might become pregnant.

Reported side effects. Both sources describe adverse effects as generally mild and infrequent: digestive upset, diarrhoea, headache, dizziness, fatigue, hot flushes. NCCIH notes it has been used safely in studies for up to three years. Rare serious events including liver injury and pancreatitis have been reported, causation unclear.

What this evidence does not show

Five things, stated plainly, because the incumbent pages in this niche mostly sell prostate supplements and have an incentive to leave them out.

It does not show that saw palmetto raises testosterone. No trial has reported that.
It does not show that saw palmetto relieves urinary symptoms. Two large publicly funded trials and a 27-trial Cochrane update point the other way. Nothing here should be read as suggesting any supplement supports, improves or treats prostate health, benign prostatic hyperplasia or urinary symptoms.
It does not show the DHT hypothesis is wrong. It shows the hypothesis is untested at the endpoint a vitality-blend buyer cares about.
It does not tell you anything about a blend. Trial results attach to a specific extract at a specific dose. A finished multi-botanical capsule has not been trialled just because one ingredient has.
It does not replace a doctor. Persistent urinary changes, blood in the urine, pain or a sudden change in flow are reasons to see a clinician promptly.

How to apply this to a label you are looking at

Three practical checks, in order.

1. Find the milligram figure. The trial dose is 320 mg a day of a standardised extract. If a label declares saw palmetto only inside a blend total, you cannot know whether you are getting 320 mg or 32 mg. Primordial Vigor X publishes an 870 mg once-daily blend of three botanicals but no verified per-ingredient breakdown, so its saw palmetto content cannot be mapped onto the 320 mg used in CAMUS or STEP. Check the Supplement Facts panel on the official store.

2. Check what kind of extract it is. CAMUS used an ethanolic extract; most of the older European literature used a lipidosterolic extract standardised to fatty acids. "Saw palmetto powder" is not the same material as either.

3. Match the claim to the evidence. If the pitch is urinary comfort, the large trials do not support it. If the pitch is that saw palmetto is there for DHT-pathway reasons, that is an honest description of a mechanism — provided it is not dressed up as a proven result.

There is a full breakdown of the formula on the Primordial Vigor X review page, our companion review of Tongkat Ali and Tribulus for testosterone and male vitality covers the other two botanicals, and lifestyle versus supplements for testosterone puts the effect sizes side by side.

Frequently asked questions

What did the CAMUS trial find about saw palmetto?

CAMUS randomised 369 men aged 45 and over to placebo or saw palmetto at escalating doses of 320 mg, then 640 mg, then 960 mg a day across 72 weeks. Symptom scores fell in both groups, but no more on saw palmetto than on placebo: the mean AUA Symptom Index change was -2.20 points on saw palmetto and -2.99 on placebo. Barry and colleagues published it in JAMA in 2011.

Does saw palmetto raise testosterone?

No published trial shows saw palmetto raising testosterone, and that is not why it appears in male vitality blends. Laboratory work indicates it interferes with 5-alpha-reductase, the enzyme that converts testosterone into dihydrotestosterone, a different pathway from testosterone production. Whether that effect produces any measurable change at supplement doses has not been shown in a human trial.

Does saw palmetto interfere with a PSA test?

The best evidence says it does not. In the CAMUS PSA analysis published in the Journal of Urology in 2013, the mean PSA change was 0.16 ng/mL on placebo and 0.23 ng/mL on saw palmetto, even at 960 mg a day. NCCIH states that saw palmetto does not appear to affect PSA readings.

Is saw palmetto safe to take with blood thinners?

Ask a doctor before combining them. The Memorial Sloan Kettering herb monograph advises people taking warfarin, antiplatelet drugs or NSAIDs to avoid saw palmetto because of reported bruising and bleeding, and the Merck Manual gives the same caution. The CAMUS safety analysis found no significant toxicity at up to three times the usual dose over 18 months, but a screened trial population is not your medication list.

Why is saw palmetto in a male vitality supplement at all?

Because of the DHT pathway rationale rather than the urinary trials. Formulators include it on the basis of laboratory evidence that it inhibits 5-alpha-reductase. That is a mechanism, not a proven outcome. Primordial Vigor X lists saw palmetto berry as one of three botanicals inside an 870 mg blend and publishes no per-ingredient milligram amount, so its dose cannot be compared against the 320 mg used in the trials.

Medical note: this article is general information, not medical advice, and it reports trial outcomes for an ingredient rather than making any claim about a product. Primordial Vigor X is a dietary supplement and is not intended to diagnose, treat, cure or prevent any disease. Speak to a healthcare professional before starting any supplement, particularly if you take anticoagulants or antiplatelet medication, are managing a prostate or hormonal condition, or have surgery scheduled. Urinary symptoms should be assessed by a clinician. This product is for adult men only.

Scientific references

Primordial Vigor X Editorial Team

We are an independent affiliate publisher covering male-vitality supplements. We read the primary literature and the product label, cite our sources, and flag weak evidence rather than paper over it.

See the full formula and current pricing

Three named botanicals in one daily capsule, a 60-day money-back guarantee handled by the seller, and no subscription.

Order Primordial Vigor X Now